Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Where this comes from
- Record sourced from PubMed, PMID 24719487.
- Also identified by DOI 10.1212/WNL.0000000000000390.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
After chronic levodopa use, many patients with Parkinson disease (PD) develop involuntary movements. Whether disabling or minor, levodopa-induced dyskinesia (LID) constitutes an undesirable outcome calling for better treatment strategies. Options for managing LID include delaying its onset by combining a dopaminergic agonist with levodopa from the start(1) or symptomatic control using amantadine. However, fundamental questions about LID remain: by what mechanisms does it develop, and why don't all patients go on to experience LID after sustained levodopa exposure?
Medical subject headings
- Antiparasitic Agents
- Dyskinesia, Drug-Induced
- Levodopa
- Presynaptic Terminals